[en] Muscular dystrophies are characterized by weakness and wasting of skeletal muscle tissues. Several drugs targeting the myostatin pathway have been used in clinical trials to increase muscle mass and function but most showed limited efficacy. Here we show that the expression of components of the myostatin signaling pathway is downregulated in muscle wasting or atrophying diseases, with a decrease of myostatin and activin receptor, and an increase of the myostatin antagonist, follistatin. We also provide in vivo evidence in the congenital myotubular myopathy mouse model (knock-out for the myotubularin coding gene Mtm1) that a down-regulated myostatin pathway can be reactivated by correcting the underlying gene defect. Our data may explain the poor clinical efficacy of anti-myostatin approaches in several of the clinical studies and the apparent contradictory results in mice regarding the efficacy of anti-myostatin approaches and may inform patient selection and stratification for future trials.
Disciplines :
Pediatrics Neurology
Author, co-author :
Mariot, Virginie
Joubert, Romain
Hourde, Christophe
Feasson, Leonard
Hanna, Michael
Muntoni, Francesco
Maisonobe, Thierry
Servais, Laurent ; Centre Hospitalier Universitaire de Liège - CHU > Service de pédiatrie (CHR)
McPherron, A. C., Lawler, A. M. & Lee, S. J. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 387, 83-90 (1997).
Lee, S. J. Regulation of muscle mass by myostatin. Annu. Rev. Cell Dev. Biol. 20, 61-86 (2004).
Schuelke, M. et al. Myostatin mutation associated with gross muscle hypertrophy in a child. N. Engl. J. Med. 350, 2682-2688 (2004).
Lee, S. J. & McPherron, A. C. Regulation of myostatin activity and muscle growth. Proc. Natl Acad. Sci. USA 98, 9306-9311 (2001).
Lee, S. J. Extracellular regulation of myostatin: a molecular rheostat for muscle mass. Immunol. Endocr. Metab. Agents Med. Chem. 10, 183-194 (2010).
Cohen, S., Nathan, J. A. & Goldberg, A. L. Muscle wasting in disease: molecular mechanisms and promising therapies. Nat. Rev. Drug. Discov. 14, 58-74 (2015).
Garber, K. No longer going to waste. Nat. Biotechnol. 34, 458-461 (2016).
Wagner, K. R. et al. A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann. Neurol. 63, 561-571 (2008).
Campbell, C. et al. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: results of a randomized, placebocontrolled clinical trial. Muscle Nerve 55, 458-464 (2016).
Al-Zaidy, S. A. et al. Follistatin gene therapy improves ambulation in becker muscular dystrophy. J. Neuromuscul. Dis. 2, 185-192 (2015).
Mendell, J. R. et al. A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. Mol. Ther. 23, 192-201 (2015).
Mendell, J. R. et al. Follistatin gene therapy for sporadic inclusion body myositis improves functional outcomes. Mol. Ther. 25, 870-879 (2017).
Amato, A. A. et al. Treatment of sporadic inclusion body myositis with bimagrumab. Neurology 83, 2239-2246 (2014).
Dumonceaux, J. et al. Combination of myostatin pathway interference and dystrophin rescue enhances tetanic and specific force in dystrophic mdx mice. Mol. Ther. 18, 881-887 (2010).
Bechir, N. et al. ActRIIB blockade increases force-generating capacity and preserves energy supply in exercising mdx mouse muscle in vivo. FASEB J. 30, 3551-3562 (2016).
Burch, P. M. et al. Reduced serum myostatin concentrations associated with genetic muscle disease progression. J. Neurol. 264, 541-553 (2017).
Anaya-Segura, M. A. et al. Non-invasive biomarkers for duchenne muscular dystrophy and carrier detection. Molecules 20, 11154-11172 (2015).
Awano, H. et al. Wide ranges of serum myostatin concentrations in Duchenne muscular dystrophy patients. Clin. Chim. Acta 391, 115-117 (2008).
Flanigan, K. M. Duchenne and becker muscular dystrophies. Neurol. Clin. 32, 671-688 (2014).
Farrar, M. A. et al. Emerging therapies and challenges in spinal muscular atrophy. Ann. Neurol. 81, 355-368 (2016).
Needham, M. & Mastaglia, F. L. Sporadic inclusion body myositis: a review of recent clinical advances and current approaches to diagnosis and treatment. Clin. Neurophysiol. 127, 1764-1773 (2016).
Wang, L. H. & Tawil, R. Facioscapulohumeral dystrophy. Curr. Neurol. Neurosci. Rep. 16, 66 (2016).
Gilhus, N. E. Myasthenia gravis. N. Engl. J. Med. 375, 2570-2581 (2016).
Schiaffino, S. et al. Developmental myosins: expression patterns and functional significance. Skelet. Muscle 5, 22 (2015).
Jungbluth, H., Wallgren-Pettersson, C. & Laporte, J. Centronuclear (myotubular) myopathy. Orphanet. J. Rare Dis. 3, 26 (2008).
Buj-Bello, A. et al. AAV-mediated intramuscular delivery of myotubularin corrects the myotubular myopathy phenotype in targeted murine muscle and suggests a function in plasma membrane homeostasis. Hum. Mol. Genet. 17, 2132-2143 (2008).
Childers, M. K. et al. Gene therapy prolongs survival and restores function in murine and canine models of myotubular myopathy. Sci. Transl. Med. 6, 220ra210 (2014).
Amato, A.A. et al., A randomized, double-blind, placebo-controlled study of bimagrumab in patients with sporadic inclusion body myositis. Arthritis Rheumatol. 68 http://acrabstracts.org/abstract/a-randomized-double-blindplacebo-controlled-study-of-bimagrumab-in-patients-with-sporadic-inclusionbody-myositis/ (2016).
Singh, P. et al. Translational pharmacokinetic/pharmacodynamic analysis of MYO-029 antibody for muscular dystrophy. Clin. Transl. Sci. 9, 302-310 (2016).
Lee, S. J. et al. Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc. Natl Acad. Sci. USA 102, 18117-18122 (2005).
Latres, E. et al. Activin A more prominently regulates muscle mass in primates than does GDF8. Nat. Commun. 8, 15153 (2017).
Lu-Nguyen, N. B. et al. Combination antisense treatment for destructive exon skipping of myostatin and open reading frame rescue of dystrophin in neonatal mdx mice. Mol. Ther. 23, 1341-1348 (2015).
Pastoret, C. & Sebille, A. Time course study of the isometric contractile properties of mdx mouse striated muscles. J. Muscle Res. Cell Motil. 14, 423-431 (1993).
Pastoret, C. & Sebille, A. mdx mice show progressive weakness and muscle deterioration with age. J. Neurol. Sci. 129, 97-105 (1995).
Buj-Bello, A. et al. The lipid phosphatase myotubularin is essential for skeletal muscle maintenance but not for myogenesis in mice. Proc. Natl Acad. Sci. USA 99, 15060-15065 (2002).
Bartoli, M. et al. AAV-mediated delivery of a mutated myostatin propeptide ameliorates calpain 3 but not alpha-sarcoglycan deficiency. Gene. Ther. 14, 733-740 (2007).
Mariot, V. et al. Correlation between low FAT1 expression and early affected muscle in facioscapulohumeral muscular dystrophy. Ann. Neurol. 78, 387-400 (2015).
Bustin, S. A. et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin. Chem. 55, 611-622 (2009).
